Amongst sufferers with untreated, superior HER2-mutated non-small cell lung most cancers (NSCLC), remedy with Hernexeos (zongertinib) was related to a big and clinically significant profit, medical trial outcomes have proven.
Outcomes from the part 1 Beamion LUNG-1 trial had been introduced on the European Society for Medical Oncology Congress 2025.
The target response fee (ORR) was 77%, with an entire response fee of 8% and a partial response fee of 69%. The illness management fee was 96% with a secure illness fee of 19% and a progressive illness fee of 1%.
Glossary
Goal Response Price (ORR): the proportion of sufferers whose most cancers shrinks (partial response) or disappears (full response) after remedy.
Illness Management Price (DCR): the proportion of sufferers whose most cancers both shrinks, disappears or stops rising for a time frame after remedy.
Length of Response (DoR): how lengthy a most cancers continues to remain smaller or gone after it first responds to remedy.
Development-Free Survival (PFS): the size of time throughout and after remedy that the most cancers doesn’t worsen.
ECOG Efficiency Standing: a scale docs use to explain how properly an individual can do day by day actions. It ranges from 0 (totally lively) to five (useless).
Interstitial Lung Illness / Pneumonitis: a gaggle of situations that trigger irritation and scarring within the lungs, typically as a facet impact of most cancers remedy.
Alanine Aminotransferase (ALT) Elevated: a higher-than-normal degree of an enzyme known as ALT within the blood, which can be an indication of liver irritation or injury.
Aspartate Aminotransferase (AST) Elevated: a higher-than-normal degree of an enzyme known as AST within the blood, which might additionally recommend liver irritation or injury.
Dysgeusia: a change in how issues style.
The median time to goal response was 1.4 months, and on the time of knowledge cutoff, 47% of sufferers remained on remedy.
The median follow-up for period of response (DOR) was 9.7 months, and the six-month DOR fee was 80%. The median follow-up for progression-free survival (PFS) was 11.6 months, and the six-month PFS fee was 79%.
“[Hernexeos] given as a first-line remedy demonstrated important and clinically significant profit in treatment-naïve sufferers with superior HER2-mutant NSCLC,” Sanjay Popat, advisor medical oncologist, head of the Lung Unit, and lead for the Lung Most cancers Analysis Programme at The Royal Marsden NHS Basis Belief, acknowledged in the course of the presentation.
A complete of 74 sufferers got 120 mg of Hernexeos. Of notice, two sufferers had obtained prior remedy. The presentation targeted on cohort 2, which enrolled sufferers who had been treatment-naïve and had a tyrosine kinase area (TKD) mutation.
Sufferers had been included in the event that they had been 18 years or older with superior/metastatic non-squamous HER2-mutated NSCLC with a number of measurable non-central nervous system lesions, and an ECOG efficiency standing of 0 or 1. Moreover, sufferers who had secure/asymptomatic mind metastases had been eligible for remedy.
The median affected person age was 67 years, 40% of sufferers had been between 65 and 74 years previous, and 18% had been 75 years or older. Moreover, 46% of sufferers had been Asian in contrast with 45% who weren’t, 64% of sufferers had by no means used tobacco, 30% had mind metastases, and 66% had A775_G776insYVMA.
Relating to security, 91% of sufferers reported treatment-related unwanted side effects, with 18% reporting a grade 3 (extreme) treatment-related facet impact. No grade 4 (life-threatening) or 5 (deadly) treatment-related unwanted side effects had been reported. A complete of 15% of sufferers had unwanted side effects resulting in dose reductions, and 9% had unwanted side effects resulting in discontinuation. There have been two circumstances of interstitial lung illness/pneumonitis, each of which had been grade 2.
The most typical TRAEs included diarrhea (54%), rash (23%), alanine aminotransferase elevated (18%), aspartate aminotransferase elevated (16%), dysgeusia (16%), and nausea (16%). Popat famous that the protection profile remained in step with beforehand reported information. Moreover, there was a low incidence of grade 3 or increased unwanted side effects.
In August 2025, the FDA gave accelerated approval to Hernexeos for sufferers with beforehand handled metastatic or unresectable non-squamous NSCLC who had HER2 TKD activating mutations, as detected by an FDA-approved check.2
References
- “Zongertinib as first-line remedy in sufferers with superior HER2-mutant NSCLC: Beamion LUNG-1,” by Sanjay Popat, et al. Offered on the European Society for Medical Oncology Congress 2025; October 17-21, 2025; Berlin, Germany. Summary LBA74.
- “FDA grants accelerated approval to zongertinib for non-squamous NSCLC with HER2 TKD activating mutations,” FDA; https://tinyurl.com/bdh2d4uc
For extra information on most cancers updates, analysis and training,
